nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Sunitinib—kidney cancer	0.662	1	CrCtD
Metoclopramide—Procainamide—Sunitinib—kidney cancer	0.237	1	CrCrCtD
Metoclopramide—CYP2D6—Temsirolimus—kidney cancer	0.0115	0.372	CbGbCtD
Metoclopramide—CYP2D6—Pazopanib—kidney cancer	0.00604	0.195	CbGbCtD
Metoclopramide—CYP2D6—Erlotinib—kidney cancer	0.00431	0.139	CbGbCtD
Metoclopramide—CYP2D6—Sorafenib—kidney cancer	0.0035	0.113	CbGbCtD
Metoclopramide—CYP2D6—Vinblastine—kidney cancer	0.00346	0.112	CbGbCtD
Metoclopramide—CYP2D6—Doxorubicin—kidney cancer	0.00213	0.0687	CbGbCtD
Metoclopramide—Sunitinib—DAPK1—kidney cancer	0.000528	0.191	CrCbGaD
Metoclopramide—Sunitinib—LRRK2—kidney cancer	0.000372	0.135	CrCbGaD
Metoclopramide—Sunitinib—FLT1—kidney cancer	0.000265	0.0961	CrCbGaD
Metoclopramide—Sunitinib—ALK—kidney cancer	0.000265	0.0961	CrCbGaD
Metoclopramide—Oxybuprocaine—BCHE—kidney cancer	0.000196	0.0711	CrCbGaD
Metoclopramide—Chloroprocaine—BCHE—kidney cancer	0.000182	0.0661	CrCbGaD
Metoclopramide—Cinchocaine—BCHE—kidney cancer	0.000174	0.0631	CrCbGaD
Metoclopramide—Procaine—BCHE—kidney cancer	0.000174	0.0631	CrCbGaD
Metoclopramide—Sunitinib—KDR—kidney cancer	0.000166	0.0602	CrCbGaD
Metoclopramide—Sunitinib—KIT—kidney cancer	0.000157	0.0568	CrCbGaD
Metoclopramide—Procainamide—ACHE—kidney cancer	0.000153	0.0555	CrCbGaD
Metoclopramide—Flushing—Dactinomycin—kidney cancer	0.000123	0.00268	CcSEcCtD
Metoclopramide—Muscle spasms—Sorafenib—kidney cancer	0.000122	0.00265	CcSEcCtD
Metoclopramide—Anxiety—Erlotinib—kidney cancer	0.00012	0.0026	CcSEcCtD
Metoclopramide—Oedema—Everolimus—kidney cancer	0.000119	0.00259	CcSEcCtD
Metoclopramide—Blood disorder—Doxorubicin—kidney cancer	0.000119	0.00258	CcSEcCtD
Metoclopramide—Hypersensitivity—Temsirolimus—kidney cancer	0.000118	0.00257	CcSEcCtD
Metoclopramide—Hallucination—Vincristine—kidney cancer	0.000118	0.00256	CcSEcCtD
Metoclopramide—Atrial fibrillation—Capecitabine—kidney cancer	0.000118	0.00256	CcSEcCtD
Metoclopramide—Renal impairment—Capecitabine—kidney cancer	0.000117	0.00255	CcSEcCtD
Metoclopramide—Muscle spasms—Sunitinib—kidney cancer	0.000117	0.00255	CcSEcCtD
Metoclopramide—Agranulocytosis—Gemcitabine—kidney cancer	0.000117	0.00254	CcSEcCtD
Metoclopramide—Tachycardia—Everolimus—kidney cancer	0.000116	0.00253	CcSEcCtD
Metoclopramide—Angioedema—Sorafenib—kidney cancer	0.000116	0.00252	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—kidney cancer	0.000115	0.00251	CcSEcCtD
Metoclopramide—Oedema—Erlotinib—kidney cancer	0.000115	0.0025	CcSEcCtD
Metoclopramide—Asthenia—Temsirolimus—kidney cancer	0.000115	0.0025	CcSEcCtD
Metoclopramide—Leukopenia—Sorafenib—kidney cancer	0.000114	0.00247	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—kidney cancer	0.000113	0.00245	CcSEcCtD
Metoclopramide—Angioedema—Sunitinib—kidney cancer	0.000112	0.00242	CcSEcCtD
Metoclopramide—Hypotension—Everolimus—kidney cancer	0.000111	0.00242	CcSEcCtD
Metoclopramide—Neutropenia—Paclitaxel—kidney cancer	0.00011	0.00239	CcSEcCtD
Metoclopramide—Diarrhoea—Temsirolimus—kidney cancer	0.00011	0.00238	CcSEcCtD
Metoclopramide—Hypertension—Sorafenib—kidney cancer	0.00011	0.00238	CcSEcCtD
Metoclopramide—Leukopenia—Sunitinib—kidney cancer	0.000109	0.00237	CcSEcCtD
Metoclopramide—Pollakiuria—Paclitaxel—kidney cancer	0.000109	0.00236	CcSEcCtD
Metoclopramide—Asthenia—Pazopanib—kidney cancer	0.000108	0.00236	CcSEcCtD
Metoclopramide—Insomnia—Everolimus—kidney cancer	0.000108	0.00234	CcSEcCtD
Metoclopramide—Dyspnoea—Everolimus—kidney cancer	0.000106	0.00231	CcSEcCtD
Metoclopramide—Cardiac arrest—Capecitabine—kidney cancer	0.000106	0.00231	CcSEcCtD
Metoclopramide—Somnolence—Everolimus—kidney cancer	0.000106	0.0023	CcSEcCtD
Metoclopramide—Dizziness—Temsirolimus—kidney cancer	0.000106	0.0023	CcSEcCtD
Metoclopramide—Convulsion—Sunitinib—kidney cancer	0.000106	0.0023	CcSEcCtD
Metoclopramide—Dyskinesia—Doxorubicin—kidney cancer	0.000106	0.00229	CcSEcCtD
Metoclopramide—Hypertension—Sunitinib—kidney cancer	0.000105	0.00229	CcSEcCtD
Metoclopramide—Depression—Paclitaxel—kidney cancer	0.000105	0.00227	CcSEcCtD
Metoclopramide—Insomnia—Erlotinib—kidney cancer	0.000104	0.00226	CcSEcCtD
Metoclopramide—Leukopenia—Dactinomycin—kidney cancer	0.000103	0.00225	CcSEcCtD
Metoclopramide—Diarrhoea—Pazopanib—kidney cancer	0.000103	0.00225	CcSEcCtD
Metoclopramide—Fatigue—Everolimus—kidney cancer	0.000103	0.00224	CcSEcCtD
Metoclopramide—Dyspnoea—Erlotinib—kidney cancer	0.000103	0.00223	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—kidney cancer	0.000102	0.00222	CcSEcCtD
Metoclopramide—Rash—Temsirolimus—kidney cancer	0.000101	0.0022	CcSEcCtD
Metoclopramide—Dermatitis—Temsirolimus—kidney cancer	0.000101	0.0022	CcSEcCtD
Metoclopramide—Headache—Temsirolimus—kidney cancer	0.0001	0.00218	CcSEcCtD
Metoclopramide—Dizziness—Pazopanib—kidney cancer	9.99e-05	0.00217	CcSEcCtD
Metoclopramide—Oedema—Sunitinib—kidney cancer	9.96e-05	0.00217	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Doxorubicin—kidney cancer	9.92e-05	0.00216	CcSEcCtD
Metoclopramide—Fatigue—Erlotinib—kidney cancer	9.92e-05	0.00216	CcSEcCtD
Metoclopramide—Feeling abnormal—Vinblastine—kidney cancer	9.87e-05	0.00214	CcSEcCtD
Metoclopramide—Feeling abnormal—Everolimus—kidney cancer	9.83e-05	0.00214	CcSEcCtD
Metoclopramide—Asthma—Capecitabine—kidney cancer	9.66e-05	0.0021	CcSEcCtD
Metoclopramide—Bradycardia—Paclitaxel—kidney cancer	9.59e-05	0.00208	CcSEcCtD
Metoclopramide—Rash—Pazopanib—kidney cancer	9.52e-05	0.00207	CcSEcCtD
Metoclopramide—Nausea—Temsirolimus—kidney cancer	9.52e-05	0.00207	CcSEcCtD
Metoclopramide—Dermatitis—Pazopanib—kidney cancer	9.51e-05	0.00207	CcSEcCtD
Metoclopramide—Bronchospasm—Capecitabine—kidney cancer	9.5e-05	0.00206	CcSEcCtD
Metoclopramide—Agitation—Vincristine—kidney cancer	9.49e-05	0.00206	CcSEcCtD
Metoclopramide—Headache—Pazopanib—kidney cancer	9.46e-05	0.00206	CcSEcCtD
Metoclopramide—Oedema—Dactinomycin—kidney cancer	9.43e-05	0.00205	CcSEcCtD
Metoclopramide—Body temperature increased—Everolimus—kidney cancer	9.43e-05	0.00205	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—kidney cancer	9.42e-05	0.00205	CcSEcCtD
Metoclopramide—Leukopenia—Vincristine—kidney cancer	9.24e-05	0.00201	CcSEcCtD
Metoclopramide—Dyspnoea—Sorafenib—kidney cancer	9.23e-05	0.00201	CcSEcCtD
Metoclopramide—Body temperature increased—Erlotinib—kidney cancer	9.1e-05	0.00198	CcSEcCtD
Metoclopramide—Visual impairment—Paclitaxel—kidney cancer	9.08e-05	0.00197	CcSEcCtD
Metoclopramide—Neutropenia—Capecitabine—kidney cancer	9.03e-05	0.00196	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—kidney cancer	9.02e-05	0.00196	CcSEcCtD
Metoclopramide—Insomnia—Sunitinib—kidney cancer	9.01e-05	0.00196	CcSEcCtD
Metoclopramide—Procainamide—BCHE—kidney cancer	9.01e-05	0.0326	CrCbGaD
Metoclopramide—Nausea—Pazopanib—kidney cancer	8.97e-05	0.00195	CcSEcCtD
Metoclopramide—Convulsion—Vincristine—kidney cancer	8.94e-05	0.00194	CcSEcCtD
Metoclopramide—Fatigue—Sorafenib—kidney cancer	8.92e-05	0.00194	CcSEcCtD
Metoclopramide—Hypertension—Vincristine—kidney cancer	8.91e-05	0.00194	CcSEcCtD
Metoclopramide—Dyspnoea—Sunitinib—kidney cancer	8.88e-05	0.00193	CcSEcCtD
Metoclopramide—Hypersensitivity—Vinblastine—kidney cancer	8.82e-05	0.00192	CcSEcCtD
Metoclopramide—Hypersensitivity—Everolimus—kidney cancer	8.79e-05	0.00191	CcSEcCtD
Metoclopramide—Leukopenia—Gemcitabine—kidney cancer	8.77e-05	0.00191	CcSEcCtD
Metoclopramide—Flushing—Paclitaxel—kidney cancer	8.74e-05	0.0019	CcSEcCtD
Metoclopramide—Asthenia—Vinblastine—kidney cancer	8.59e-05	0.00187	CcSEcCtD
Metoclopramide—Fatigue—Sunitinib—kidney cancer	8.59e-05	0.00187	CcSEcCtD
Metoclopramide—Depression—Capecitabine—kidney cancer	8.59e-05	0.00187	CcSEcCtD
Metoclopramide—Asthenia—Everolimus—kidney cancer	8.56e-05	0.00186	CcSEcCtD
Metoclopramide—Hypertension—Gemcitabine—kidney cancer	8.46e-05	0.00184	CcSEcCtD
Metoclopramide—Oedema—Vincristine—kidney cancer	8.43e-05	0.00183	CcSEcCtD
Metoclopramide—Jaundice—Capecitabine—kidney cancer	8.39e-05	0.00182	CcSEcCtD
Metoclopramide—Asthenia—Erlotinib—kidney cancer	8.26e-05	0.00179	CcSEcCtD
Metoclopramide—Urticaria—Sorafenib—kidney cancer	8.22e-05	0.00179	CcSEcCtD
Metoclopramide—Diarrhoea—Vinblastine—kidney cancer	8.19e-05	0.00178	CcSEcCtD
Metoclopramide—Body temperature increased—Sorafenib—kidney cancer	8.18e-05	0.00178	CcSEcCtD
Metoclopramide—Diarrhoea—Everolimus—kidney cancer	8.16e-05	0.00177	CcSEcCtD
Metoclopramide—Fatigue—Dactinomycin—kidney cancer	8.13e-05	0.00177	CcSEcCtD
Metoclopramide—Agranulocytosis—Capecitabine—kidney cancer	8.04e-05	0.00175	CcSEcCtD
Metoclopramide—Oedema—Gemcitabine—kidney cancer	7.99e-05	0.00174	CcSEcCtD
Metoclopramide—Nervousness—Paclitaxel—kidney cancer	7.96e-05	0.00173	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—kidney cancer	7.94e-05	0.00173	CcSEcCtD
Metoclopramide—Dizziness—Vinblastine—kidney cancer	7.92e-05	0.00172	CcSEcCtD
Metoclopramide—Dizziness—Everolimus—kidney cancer	7.89e-05	0.00171	CcSEcCtD
Metoclopramide—Muscle spasms—Paclitaxel—kidney cancer	7.88e-05	0.00171	CcSEcCtD
Metoclopramide—Body temperature increased—Sunitinib—kidney cancer	7.87e-05	0.00171	CcSEcCtD
Metoclopramide—Diarrhoea—Erlotinib—kidney cancer	7.87e-05	0.00171	CcSEcCtD
Metoclopramide—Hypotension—Vincristine—kidney cancer	7.87e-05	0.00171	CcSEcCtD
Metoclopramide—Bradycardia—Capecitabine—kidney cancer	7.87e-05	0.00171	CcSEcCtD
Metoclopramide—Feeling abnormal—Dactinomycin—kidney cancer	7.77e-05	0.00169	CcSEcCtD
Metoclopramide—Tremor—Paclitaxel—kidney cancer	7.68e-05	0.00167	CcSEcCtD
Metoclopramide—Hypersensitivity—Sorafenib—kidney cancer	7.63e-05	0.00166	CcSEcCtD
Metoclopramide—Insomnia—Vincristine—kidney cancer	7.62e-05	0.00166	CcSEcCtD
Metoclopramide—Dizziness—Erlotinib—kidney cancer	7.61e-05	0.00165	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—kidney cancer	7.57e-05	0.00165	CcSEcCtD
Metoclopramide—Agitation—Paclitaxel—kidney cancer	7.53e-05	0.00164	CcSEcCtD
Metoclopramide—Rash—Everolimus—kidney cancer	7.52e-05	0.00163	CcSEcCtD
Metoclopramide—Dermatitis—Everolimus—kidney cancer	7.51e-05	0.00163	CcSEcCtD
Metoclopramide—Headache—Vinblastine—kidney cancer	7.5e-05	0.00163	CcSEcCtD
Metoclopramide—Angioedema—Paclitaxel—kidney cancer	7.49e-05	0.00163	CcSEcCtD
Metoclopramide—Headache—Everolimus—kidney cancer	7.47e-05	0.00162	CcSEcCtD
Metoclopramide—Hypotension—Gemcitabine—kidney cancer	7.47e-05	0.00162	CcSEcCtD
Metoclopramide—Body temperature increased—Dactinomycin—kidney cancer	7.45e-05	0.00162	CcSEcCtD
Metoclopramide—Visual impairment—Capecitabine—kidney cancer	7.45e-05	0.00162	CcSEcCtD
Metoclopramide—Asthenia—Sorafenib—kidney cancer	7.43e-05	0.00161	CcSEcCtD
Metoclopramide—Leukopenia—Paclitaxel—kidney cancer	7.34e-05	0.0016	CcSEcCtD
Metoclopramide—Hypersensitivity—Sunitinib—kidney cancer	7.34e-05	0.0016	CcSEcCtD
Metoclopramide—Fatigue—Vincristine—kidney cancer	7.26e-05	0.00158	CcSEcCtD
Metoclopramide—Rash—Erlotinib—kidney cancer	7.26e-05	0.00158	CcSEcCtD
Metoclopramide—Dermatitis—Erlotinib—kidney cancer	7.25e-05	0.00158	CcSEcCtD
Metoclopramide—Palpitations—Paclitaxel—kidney cancer	7.25e-05	0.00158	CcSEcCtD
Metoclopramide—Insomnia—Gemcitabine—kidney cancer	7.23e-05	0.00157	CcSEcCtD
Metoclopramide—Headache—Erlotinib—kidney cancer	7.21e-05	0.00157	CcSEcCtD
Metoclopramide—Flushing—Capecitabine—kidney cancer	7.17e-05	0.00156	CcSEcCtD
Metoclopramide—Asthenia—Sunitinib—kidney cancer	7.15e-05	0.00155	CcSEcCtD
Metoclopramide—Dyspnoea—Gemcitabine—kidney cancer	7.13e-05	0.00155	CcSEcCtD
Metoclopramide—Nausea—Vinblastine—kidney cancer	7.11e-05	0.00155	CcSEcCtD
Metoclopramide—Somnolence—Gemcitabine—kidney cancer	7.11e-05	0.00154	CcSEcCtD
Metoclopramide—Convulsion—Paclitaxel—kidney cancer	7.1e-05	0.00154	CcSEcCtD
Metoclopramide—Nausea—Everolimus—kidney cancer	7.08e-05	0.00154	CcSEcCtD
Metoclopramide—Diarrhoea—Sorafenib—kidney cancer	7.08e-05	0.00154	CcSEcCtD
Metoclopramide—Hypertension—Paclitaxel—kidney cancer	7.08e-05	0.00154	CcSEcCtD
Metoclopramide—Anxiety—Paclitaxel—kidney cancer	6.96e-05	0.00151	CcSEcCtD
Metoclopramide—Hypersensitivity—Dactinomycin—kidney cancer	6.95e-05	0.00151	CcSEcCtD
Metoclopramide—Fatigue—Gemcitabine—kidney cancer	6.89e-05	0.0015	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—kidney cancer	6.85e-05	0.00149	CcSEcCtD
Metoclopramide—Dizziness—Sorafenib—kidney cancer	6.85e-05	0.00149	CcSEcCtD
Metoclopramide—Nausea—Erlotinib—kidney cancer	6.83e-05	0.00149	CcSEcCtD
Metoclopramide—Diarrhoea—Sunitinib—kidney cancer	6.82e-05	0.00148	CcSEcCtD
Metoclopramide—Asthenia—Dactinomycin—kidney cancer	6.77e-05	0.00147	CcSEcCtD
Metoclopramide—Confusional state—Paclitaxel—kidney cancer	6.75e-05	0.00147	CcSEcCtD
Metoclopramide—Oedema—Paclitaxel—kidney cancer	6.69e-05	0.00145	CcSEcCtD
Metoclopramide—Body temperature increased—Vincristine—kidney cancer	6.66e-05	0.00145	CcSEcCtD
Metoclopramide—Dizziness—Sunitinib—kidney cancer	6.59e-05	0.00143	CcSEcCtD
Metoclopramide—Feeling abnormal—Gemcitabine—kidney cancer	6.59e-05	0.00143	CcSEcCtD
Metoclopramide—Tachycardia—Paclitaxel—kidney cancer	6.53e-05	0.00142	CcSEcCtD
Metoclopramide—Rash—Sorafenib—kidney cancer	6.53e-05	0.00142	CcSEcCtD
Metoclopramide—Dermatitis—Sorafenib—kidney cancer	6.52e-05	0.00142	CcSEcCtD
Metoclopramide—Headache—Sorafenib—kidney cancer	6.49e-05	0.00141	CcSEcCtD
Metoclopramide—Muscle spasms—Capecitabine—kidney cancer	6.47e-05	0.00141	CcSEcCtD
Metoclopramide—Diarrhoea—Dactinomycin—kidney cancer	6.45e-05	0.0014	CcSEcCtD
Metoclopramide—Body temperature increased—Gemcitabine—kidney cancer	6.32e-05	0.00137	CcSEcCtD
Metoclopramide—Tremor—Capecitabine—kidney cancer	6.3e-05	0.00137	CcSEcCtD
Metoclopramide—Rash—Sunitinib—kidney cancer	6.28e-05	0.00137	CcSEcCtD
Metoclopramide—Dermatitis—Sunitinib—kidney cancer	6.27e-05	0.00136	CcSEcCtD
Metoclopramide—Hypotension—Paclitaxel—kidney cancer	6.25e-05	0.00136	CcSEcCtD
Metoclopramide—Headache—Sunitinib—kidney cancer	6.24e-05	0.00136	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—kidney cancer	6.22e-05	0.00135	CcSEcCtD
Metoclopramide—Hypersensitivity—Vincristine—kidney cancer	6.21e-05	0.00135	CcSEcCtD
Metoclopramide—Nausea—Sorafenib—kidney cancer	6.15e-05	0.00134	CcSEcCtD
Metoclopramide—Insomnia—Paclitaxel—kidney cancer	6.05e-05	0.00132	CcSEcCtD
Metoclopramide—Asthenia—Vincristine—kidney cancer	6.04e-05	0.00131	CcSEcCtD
Metoclopramide—Leukopenia—Capecitabine—kidney cancer	6.02e-05	0.00131	CcSEcCtD
Metoclopramide—Dyspnoea—Paclitaxel—kidney cancer	5.97e-05	0.0013	CcSEcCtD
Metoclopramide—Somnolence—Paclitaxel—kidney cancer	5.95e-05	0.00129	CcSEcCtD
Metoclopramide—Palpitations—Capecitabine—kidney cancer	5.95e-05	0.00129	CcSEcCtD
Metoclopramide—Rash—Dactinomycin—kidney cancer	5.95e-05	0.00129	CcSEcCtD
Metoclopramide—Nausea—Sunitinib—kidney cancer	5.92e-05	0.00129	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—kidney cancer	5.82e-05	0.00127	CcSEcCtD
Metoclopramide—Hypertension—Capecitabine—kidney cancer	5.81e-05	0.00126	CcSEcCtD
Metoclopramide—Fatigue—Paclitaxel—kidney cancer	5.77e-05	0.00125	CcSEcCtD
Metoclopramide—Diarrhoea—Vincristine—kidney cancer	5.76e-05	0.00125	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—kidney cancer	5.75e-05	0.00125	CcSEcCtD
Metoclopramide—Asthenia—Gemcitabine—kidney cancer	5.73e-05	0.00125	CcSEcCtD
Metoclopramide—Anxiety—Capecitabine—kidney cancer	5.71e-05	0.00124	CcSEcCtD
Metoclopramide—Nausea—Dactinomycin—kidney cancer	5.6e-05	0.00122	CcSEcCtD
Metoclopramide—Dizziness—Vincristine—kidney cancer	5.57e-05	0.00121	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—kidney cancer	5.55e-05	0.00121	CcSEcCtD
Metoclopramide—Confusional state—Capecitabine—kidney cancer	5.54e-05	0.0012	CcSEcCtD
Metoclopramide—Feeling abnormal—Paclitaxel—kidney cancer	5.51e-05	0.0012	CcSEcCtD
Metoclopramide—Oedema—Capecitabine—kidney cancer	5.49e-05	0.00119	CcSEcCtD
Metoclopramide—Diarrhoea—Gemcitabine—kidney cancer	5.47e-05	0.00119	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—kidney cancer	5.41e-05	0.00118	CcSEcCtD
Metoclopramide—Tachycardia—Capecitabine—kidney cancer	5.36e-05	0.00117	CcSEcCtD
Metoclopramide—Urticaria—Paclitaxel—kidney cancer	5.32e-05	0.00116	CcSEcCtD
Metoclopramide—Rash—Vincristine—kidney cancer	5.31e-05	0.00115	CcSEcCtD
Metoclopramide—Dermatitis—Vincristine—kidney cancer	5.31e-05	0.00115	CcSEcCtD
Metoclopramide—Body temperature increased—Paclitaxel—kidney cancer	5.29e-05	0.00115	CcSEcCtD
Metoclopramide—Headache—Vincristine—kidney cancer	5.28e-05	0.00115	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—kidney cancer	5.18e-05	0.00113	CcSEcCtD
Metoclopramide—Hypotension—Capecitabine—kidney cancer	5.13e-05	0.00112	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—kidney cancer	5.07e-05	0.0011	CcSEcCtD
Metoclopramide—Rash—Gemcitabine—kidney cancer	5.04e-05	0.0011	CcSEcCtD
Metoclopramide—Dermatitis—Gemcitabine—kidney cancer	5.03e-05	0.00109	CcSEcCtD
Metoclopramide—Headache—Gemcitabine—kidney cancer	5.01e-05	0.00109	CcSEcCtD
Metoclopramide—Nausea—Vincristine—kidney cancer	5e-05	0.00109	CcSEcCtD
Metoclopramide—Insomnia—Capecitabine—kidney cancer	4.97e-05	0.00108	CcSEcCtD
Metoclopramide—Hypersensitivity—Paclitaxel—kidney cancer	4.93e-05	0.00107	CcSEcCtD
Metoclopramide—Dyspnoea—Capecitabine—kidney cancer	4.9e-05	0.00106	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—kidney cancer	4.8e-05	0.00104	CcSEcCtD
Metoclopramide—Asthenia—Paclitaxel—kidney cancer	4.8e-05	0.00104	CcSEcCtD
Metoclopramide—Nausea—Gemcitabine—kidney cancer	4.75e-05	0.00103	CcSEcCtD
Metoclopramide—Fatigue—Capecitabine—kidney cancer	4.73e-05	0.00103	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—kidney cancer	4.62e-05	0.00101	CcSEcCtD
Metoclopramide—Diarrhoea—Paclitaxel—kidney cancer	4.58e-05	0.000995	CcSEcCtD
Metoclopramide—Feeling abnormal—Capecitabine—kidney cancer	4.53e-05	0.000984	CcSEcCtD
Metoclopramide—Dizziness—Paclitaxel—kidney cancer	4.43e-05	0.000962	CcSEcCtD
Metoclopramide—Urticaria—Capecitabine—kidney cancer	4.36e-05	0.000948	CcSEcCtD
Metoclopramide—Body temperature increased—Capecitabine—kidney cancer	4.34e-05	0.000944	CcSEcCtD
Metoclopramide—Rash—Paclitaxel—kidney cancer	4.22e-05	0.000917	CcSEcCtD
Metoclopramide—Dermatitis—Paclitaxel—kidney cancer	4.22e-05	0.000916	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—kidney cancer	4.21e-05	0.000916	CcSEcCtD
Metoclopramide—Headache—Paclitaxel—kidney cancer	4.19e-05	0.000911	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—kidney cancer	4.17e-05	0.000906	CcSEcCtD
Metoclopramide—Hypersensitivity—Capecitabine—kidney cancer	4.05e-05	0.000879	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—kidney cancer	3.99e-05	0.000866	CcSEcCtD
Metoclopramide—Nausea—Paclitaxel—kidney cancer	3.97e-05	0.000864	CcSEcCtD
Metoclopramide—Asthenia—Capecitabine—kidney cancer	3.94e-05	0.000856	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—kidney cancer	3.88e-05	0.000844	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—kidney cancer	3.83e-05	0.000833	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—kidney cancer	3.76e-05	0.000817	CcSEcCtD
Metoclopramide—Diarrhoea—Capecitabine—kidney cancer	3.76e-05	0.000817	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—kidney cancer	3.74e-05	0.000814	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—kidney cancer	3.68e-05	0.0008	CcSEcCtD
Metoclopramide—Dizziness—Capecitabine—kidney cancer	3.63e-05	0.000789	CcSEcCtD
Metoclopramide—Sunitinib—ABCB1—kidney cancer	3.61e-05	0.0131	CrCbGaD
Metoclopramide—Confusional state—Doxorubicin—kidney cancer	3.57e-05	0.000776	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—kidney cancer	3.54e-05	0.000769	CcSEcCtD
Metoclopramide—Rash—Capecitabine—kidney cancer	3.46e-05	0.000753	CcSEcCtD
Metoclopramide—Dermatitis—Capecitabine—kidney cancer	3.46e-05	0.000752	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—kidney cancer	3.45e-05	0.000751	CcSEcCtD
Metoclopramide—Headache—Capecitabine—kidney cancer	3.44e-05	0.000748	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—kidney cancer	3.31e-05	0.000719	CcSEcCtD
Metoclopramide—Nausea—Capecitabine—kidney cancer	3.26e-05	0.000709	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—kidney cancer	3.2e-05	0.000696	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—kidney cancer	3.16e-05	0.000686	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—kidney cancer	3.15e-05	0.000684	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—kidney cancer	3.05e-05	0.000663	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—kidney cancer	2.92e-05	0.000634	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—kidney cancer	2.81e-05	0.000611	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—kidney cancer	2.8e-05	0.000608	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—kidney cancer	2.61e-05	0.000567	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—kidney cancer	2.54e-05	0.000552	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—kidney cancer	2.42e-05	0.000526	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—kidney cancer	2.34e-05	0.000509	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—kidney cancer	2.23e-05	0.000485	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—kidney cancer	2.23e-05	0.000485	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—kidney cancer	2.22e-05	0.000482	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—kidney cancer	2.1e-05	0.000457	CcSEcCtD
Metoclopramide—CYP2D6—Biological oxidations—POMC—kidney cancer	9.57e-06	0.000464	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—ITPR2—kidney cancer	9.47e-06	0.000459	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.46e-06	0.000458	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ABCB1—kidney cancer	9.43e-06	0.000457	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GSTP1—kidney cancer	9.32e-06	0.000452	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GSTM1—kidney cancer	9.16e-06	0.000444	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CCBL1—kidney cancer	9.03e-06	0.000438	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TP53—kidney cancer	8.99e-06	0.000436	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—ANXA1—kidney cancer	8.93e-06	0.000433	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—kidney cancer	8.84e-06	0.000429	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—APC—kidney cancer	8.82e-06	0.000428	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KIT—kidney cancer	8.82e-06	0.000428	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ABCB1—kidney cancer	8.82e-06	0.000428	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP2—kidney cancer	8.79e-06	0.000426	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKAP13—kidney cancer	8.79e-06	0.000426	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—ANXA1—kidney cancer	8.74e-06	0.000424	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CYP1A1—kidney cancer	8.68e-06	0.000421	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GSTM1—kidney cancer	8.57e-06	0.000415	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—MAPK3—kidney cancer	8.45e-06	0.00041	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—POMC—kidney cancer	8.4e-06	0.000407	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SFRP2—kidney cancer	8.34e-06	0.000404	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—BRAF—kidney cancer	8.29e-06	0.000402	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.28e-06	0.000401	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SFRP2—kidney cancer	8.16e-06	0.000396	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CYP1A1—kidney cancer	8.12e-06	0.000394	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—ANXA1—kidney cancer	8.11e-06	0.000393	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—MAPK1—kidney cancer	8.04e-06	0.00039	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GRB7—kidney cancer	8.04e-06	0.00039	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	7.99e-06	0.000387	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—ANXA1—kidney cancer	7.94e-06	0.000385	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPAT—kidney cancer	7.83e-06	0.00038	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GLIPR1—kidney cancer	7.83e-06	0.00038	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—POMC—kidney cancer	7.74e-06	0.000375	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—PIK3CA—kidney cancer	7.68e-06	0.000372	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	7.6e-06	0.000368	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—KRAS—kidney cancer	7.59e-06	0.000368	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—POMC—kidney cancer	7.58e-06	0.000367	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—POMC—kidney cancer	7.51e-06	0.000364	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ITPR2—kidney cancer	7.47e-06	0.000362	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—PIK3CA—kidney cancer	7.37e-06	0.000357	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—FH—kidney cancer	7.28e-06	0.000353	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APRT—kidney cancer	7.28e-06	0.000353	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	7.18e-06	0.000348	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.13e-06	0.000346	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—PIK3CA—kidney cancer	6.98e-06	0.000338	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—RAF1—kidney cancer	6.93e-06	0.000336	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—RELA—kidney cancer	6.89e-06	0.000334	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TP53—kidney cancer	6.88e-06	0.000333	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ERBB2—kidney cancer	6.85e-06	0.000332	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPC3—kidney cancer	6.84e-06	0.000332	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CTNNA1—kidney cancer	6.77e-06	0.000328	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MTOR—kidney cancer	6.76e-06	0.000328	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EIF4EBP1—kidney cancer	6.73e-06	0.000326	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HSPB1—kidney cancer	6.73e-06	0.000326	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—kidney cancer	6.73e-06	0.000326	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKAP13—kidney cancer	6.72e-06	0.000326	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP2—kidney cancer	6.72e-06	0.000326	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.67e-06	0.000323	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CA2—kidney cancer	6.66e-06	0.000323	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	6.59e-06	0.00032	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKAP13—kidney cancer	6.58e-06	0.000319	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP2—kidney cancer	6.58e-06	0.000319	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALAD—kidney cancer	6.49e-06	0.000314	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—POMC—kidney cancer	6.47e-06	0.000314	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CDKN1B—kidney cancer	6.35e-06	0.000308	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ST3GAL2—kidney cancer	6.33e-06	0.000307	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PSMD7—kidney cancer	6.26e-06	0.000303	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ANXA1—kidney cancer	6.26e-06	0.000303	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TSC1—kidney cancer	6.26e-06	0.000303	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL2—kidney cancer	6.21e-06	0.000301	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALDH1A1—kidney cancer	6.19e-06	0.0003	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GRB7—kidney cancer	6.15e-06	0.000298	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FLT1—kidney cancer	6.06e-06	0.000294	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—POMC—kidney cancer	6.05e-06	0.000293	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCND1—kidney cancer	6.05e-06	0.000293	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—JUN—kidney cancer	6.04e-06	0.000293	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GRB7—kidney cancer	6.02e-06	0.000292	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CTNNB1—kidney cancer	5.99e-06	0.000291	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTGS2—kidney cancer	5.99e-06	0.00029	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC5A3—kidney cancer	5.93e-06	0.000288	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PGK1—kidney cancer	5.93e-06	0.000288	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTEN—kidney cancer	5.84e-06	0.000283	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LDHB—kidney cancer	5.82e-06	0.000282	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—POMC—kidney cancer	5.72e-06	0.000277	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ITPR2—kidney cancer	5.72e-06	0.000277	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JUNB—kidney cancer	5.62e-06	0.000272	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PAK1—kidney cancer	5.62e-06	0.000272	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ITPR2—kidney cancer	5.59e-06	0.000271	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—kidney cancer	5.28e-06	0.000256	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTEN—kidney cancer	5.22e-06	0.000253	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—POMC—kidney cancer	5.19e-06	0.000252	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CTNNA1—kidney cancer	5.18e-06	0.000251	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTGS2—kidney cancer	5.16e-06	0.00025	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EIF4EBP1—kidney cancer	5.15e-06	0.00025	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HSPB1—kidney cancer	5.15e-06	0.00025	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CTNNA1—kidney cancer	5.07e-06	0.000246	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CA9—kidney cancer	5.05e-06	0.000245	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HSPB1—kidney cancer	5.04e-06	0.000244	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EIF4EBP1—kidney cancer	5.04e-06	0.000244	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK3—kidney cancer	4.99e-06	0.000242	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MYC—kidney cancer	4.86e-06	0.000235	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—kidney cancer	4.83e-06	0.000234	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TSC1—kidney cancer	4.79e-06	0.000232	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PSMD7—kidney cancer	4.79e-06	0.000232	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ANXA1—kidney cancer	4.79e-06	0.000232	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK1—kidney cancer	4.75e-06	0.00023	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ANXA1—kidney cancer	4.69e-06	0.000227	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TSC1—kidney cancer	4.69e-06	0.000227	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PSMD7—kidney cancer	4.69e-06	0.000227	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FLT1—kidney cancer	4.64e-06	0.000225	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF2—kidney cancer	4.6e-06	0.000223	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN2B—kidney cancer	4.58e-06	0.000222	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FLT1—kidney cancer	4.54e-06	0.00022	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTEN—kidney cancer	4.5e-06	0.000218	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KRAS—kidney cancer	4.49e-06	0.000217	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1R—kidney cancer	4.44e-06	0.000215	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—POMC—kidney cancer	4.38e-06	0.000212	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PAK1—kidney cancer	4.3e-06	0.000208	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JUNB—kidney cancer	4.3e-06	0.000208	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CRABP1—kidney cancer	4.29e-06	0.000208	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—POMC—kidney cancer	4.28e-06	0.000208	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—RAF1—kidney cancer	4.28e-06	0.000208	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—IL2—kidney cancer	4.23e-06	0.000205	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTEN—kidney cancer	4.21e-06	0.000204	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JUNB—kidney cancer	4.21e-06	0.000204	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PAK1—kidney cancer	4.21e-06	0.000204	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PIK3CA—kidney cancer	4.12e-06	0.0002	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ITPR2—kidney cancer	3.99e-06	0.000193	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—kidney cancer	3.99e-06	0.000193	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—POMC—kidney cancer	3.97e-06	0.000193	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—POMC—kidney cancer	3.89e-06	0.000188	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2—kidney cancer	3.84e-06	0.000186	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CA—kidney cancer	3.69e-06	0.000179	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HIF1A—kidney cancer	3.66e-06	0.000177	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TSC2—kidney cancer	3.65e-06	0.000177	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ACHE—kidney cancer	3.64e-06	0.000176	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTT1—kidney cancer	3.64e-06	0.000176	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF2—kidney cancer	3.52e-06	0.00017	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN2B—kidney cancer	3.5e-06	0.00017	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KDR—kidney cancer	3.5e-06	0.00017	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SCARB1—kidney cancer	3.44e-06	0.000167	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF2—kidney cancer	3.44e-06	0.000167	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN2B—kidney cancer	3.43e-06	0.000166	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS1—kidney cancer	3.41e-06	0.000165	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1R—kidney cancer	3.4e-06	0.000165	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PSMD7—kidney cancer	3.34e-06	0.000162	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1R—kidney cancer	3.33e-06	0.000161	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—RAF1—kidney cancer	3.28e-06	0.000159	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—kidney cancer	3.23e-06	0.000157	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APC—kidney cancer	3.22e-06	0.000156	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KIT—kidney cancer	3.22e-06	0.000156	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—RAF1—kidney cancer	3.21e-06	0.000155	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—kidney cancer	3.18e-06	0.000154	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—BCHE—kidney cancer	3.17e-06	0.000154	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—kidney cancer	3.17e-06	0.000153	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC5A5—kidney cancer	3.13e-06	0.000152	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK3—kidney cancer	3.09e-06	0.00015	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—POMC—kidney cancer	3.07e-06	0.000149	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—BRAF—kidney cancer	3.03e-06	0.000147	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.02e-06	0.000147	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—kidney cancer	2.97e-06	0.000144	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—kidney cancer	2.94e-06	0.000142	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK1—kidney cancer	2.94e-06	0.000142	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—kidney cancer	2.87e-06	0.000139	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—kidney cancer	2.81e-06	0.000136	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HIF1A—kidney cancer	2.8e-06	0.000136	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TSC2—kidney cancer	2.79e-06	0.000135	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—kidney cancer	2.77e-06	0.000134	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HIF1A—kidney cancer	2.74e-06	0.000133	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TSC2—kidney cancer	2.73e-06	0.000132	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KDR—kidney cancer	2.68e-06	0.00013	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KDR—kidney cancer	2.62e-06	0.000127	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—kidney cancer	2.55e-06	0.000124	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RAF1—kidney cancer	2.53e-06	0.000123	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTP1—kidney cancer	2.52e-06	0.000122	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RELA—kidney cancer	2.52e-06	0.000122	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—kidney cancer	2.5e-06	0.000121	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MTOR—kidney cancer	2.47e-06	0.00012	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KIT—kidney cancer	2.47e-06	0.00012	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APC—kidney cancer	2.47e-06	0.00012	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APC—kidney cancer	2.41e-06	0.000117	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KIT—kidney cancer	2.41e-06	0.000117	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ABCB1—kidney cancer	2.39e-06	0.000116	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK3—kidney cancer	2.36e-06	0.000114	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—POMC—kidney cancer	2.35e-06	0.000114	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—BRAF—kidney cancer	2.32e-06	0.000112	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1B—kidney cancer	2.32e-06	0.000112	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—kidney cancer	2.32e-06	0.000112	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	2.31e-06	0.000112	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—POMC—kidney cancer	2.3e-06	0.000111	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—BRAF—kidney cancer	2.27e-06	0.00011	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—kidney cancer	2.27e-06	0.00011	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK1—kidney cancer	2.25e-06	0.000109	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—kidney cancer	2.21e-06	0.000107	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JUN—kidney cancer	2.21e-06	0.000107	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	2.2e-06	0.000107	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.2e-06	0.000106	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CTNNB1—kidney cancer	2.19e-06	0.000106	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	2.15e-06	0.000104	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—kidney cancer	2.13e-06	0.000103	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—kidney cancer	2.12e-06	0.000103	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	2.1e-06	0.000102	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—kidney cancer	2.08e-06	0.000101	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	1.95e-06	9.45e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RAF1—kidney cancer	1.94e-06	9.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—kidney cancer	1.93e-06	9.34e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RELA—kidney cancer	1.93e-06	9.34e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—kidney cancer	1.91e-06	9.28e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	1.91e-06	9.25e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RAF1—kidney cancer	1.89e-06	9.18e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MTOR—kidney cancer	1.89e-06	9.16e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RELA—kidney cancer	1.89e-06	9.14e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—kidney cancer	1.87e-06	9.08e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MTOR—kidney cancer	1.85e-06	8.96e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK3—kidney cancer	1.82e-06	8.84e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—kidney cancer	1.77e-06	8.59e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1B—kidney cancer	1.77e-06	8.59e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	1.74e-06	8.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—kidney cancer	1.74e-06	8.41e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK1—kidney cancer	1.73e-06	8.41e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—kidney cancer	1.7e-06	8.23e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—kidney cancer	1.69e-06	8.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JUN—kidney cancer	1.69e-06	8.18e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CTNNB1—kidney cancer	1.68e-06	8.12e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—kidney cancer	1.66e-06	8.02e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JUN—kidney cancer	1.65e-06	8.01e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	1.64e-06	7.95e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—kidney cancer	1.64e-06	7.94e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—POMC—kidney cancer	1.64e-06	7.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—kidney cancer	1.63e-06	7.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—kidney cancer	1.6e-06	7.75e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—kidney cancer	1.51e-06	7.3e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—kidney cancer	1.47e-06	7.15e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—kidney cancer	1.46e-06	7.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—kidney cancer	1.44e-06	7e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK3—kidney cancer	1.39e-06	6.76e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK3—kidney cancer	1.37e-06	6.62e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—kidney cancer	1.36e-06	6.58e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—kidney cancer	1.33e-06	6.44e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK1—kidney cancer	1.33e-06	6.43e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—kidney cancer	1.31e-06	6.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK1—kidney cancer	1.3e-06	6.3e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—kidney cancer	1.25e-06	6.08e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—kidney cancer	1.23e-06	5.95e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—kidney cancer	1.15e-06	5.58e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—kidney cancer	1.14e-06	5.52e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	1.13e-06	5.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—kidney cancer	1.11e-06	5.4e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—kidney cancer	1.09e-06	5.29e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—kidney cancer	8.03e-07	3.89e-05	CbGpPWpGaD
